Anti-Rheumatic Rx
Eric Dein
1 year 10 months ago
Palliative Care & Rheum - #ACR23 @RheumNow
Consider Pall Care for Serious Illness: "high mortality risk & negatively impacts function or QoL OR strains caregivers" - thats a lot of rheum pt
@HopkinsBayview-led session, always pt-centric
@kekuchinad @MymaAlbaydaMD @jhrheumatology https://t.co/1j4lrkb5Ra
Mithu Maheswaranathan, MD
1 year 10 months ago
Clinical Year in Review at #ACR23
By @philseo (@jhrheumatology)
Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u
Dr. John Cush RheumNow
1 year 10 months ago
Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv
Aurelie Najm
1 year 10 months ago
ARTIC REWIND RCT 3 yrs csDMARD withdrawal
38% 3yrs csDMARDs free remission vs. 80% stable dose gpe
75% recovery after restart
Rx progression 19% in half dose gpe
More use bioDMARDs (18%) & GCs (50%) withdraw gpe
Trends towards lower infections
@RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS
Aurelie Najm
1 year 10 months ago
Tapering ABA vs. stable dose ABA in RA
No diff in DAS28 remission at 2 years
But…
Only in patients receiving concomitant MTX
Those tapering ABA mono also experience higher functional important
Of note: not an RCT
@RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
David Liew drdavidliew
1 year 10 months ago
Rheumatologist - pharmacist co-management of MTX initiators @GeisingerHealth Philadelphia
Having the dual skill set actually helped with adherence to guidelines vs standard care. Would be great to see how this works with implementation in RA clinics
#ACR23 ABST2484 @RheumNow https://t.co/88R1BYzYn5
sheila
1 year 10 months ago
Complements & HCQ? (Prof Petri et al)
Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole blood levels >50 ng/mL
Increasing blood levels of HCQ significantly assocd w/⬆️prob of achieving normal C4
Improving C3,C4; addtl benefit of HCQ?
#ACR23 ABST2327 @RheumNow https://t.co/5ucpXq9ngb
Eric Dein
1 year 10 months ago
TM83 #ACR23 @RheumNow
45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv
Low Ca, & Phos, ALP 239. Nml Vit D, High PTH.
DEXA: Osteoporosis
FGF23 high
PET/CT showed soft tissue density in nasal septum, few cortical breaks
Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy
Bella Mehta bella_mehta
1 year 10 months ago
Extended-Release Fluticasone Propionate for Injectable Suspension - EP-104IAR
Phase 2 Randomized (1:1), Double-blind, Vehicle-Controlled Trial
318 pts, 57% F, age 64,
Clinically and statistically significant pain relief for 14 weeks compared to vehicle
@RheumNow #ACR23 #abstL04
David Liew drdavidliew
1 year 10 months ago
If we're to summarize the challenges to making for CAR-T therapy work in a given disease, this is it:
Dr. Chyi-Song Hsieh @WUSTL #ACR23 @RheumNow https://t.co/raoHtrJ25S
Eric Dein
1 year 10 months ago
Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow
We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi
TheDaoIndex KDAO2011
1 year 10 months ago
Read my article on ACR Plenaries: Changing the Practice of Rheumatology #ACR23 @ACRheum @RheumNow @uptoTate @Yuz6Yusof @ericdeinmd
https://t.co/ql851dVzAk
Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
Nouf Al hemmadi
1 year 10 months ago
1-PJP prophylaxis or not in ANCA?
2-MTX single dose or split dose?
3-IL6 blocker early on in GCA/PMR?
4-SGLT2 in DM/Lupus nephritis?
5-Cervical cancer screening in Lupus?
6-TNF induced ILD?
https://t.co/mzGXajmQqE
@RheumNow , Daily recap
#ACR23
Poster Hall